You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for Lazabemide hydrochloride
Lazabemide hydrochloride is a selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively). Inhibits monoamine uptake at high concentrations (IC50 values are 86, 123 and > 500 μM for noradrenalin, serotonin and dopamine uptake respectively).
Technical Data for Lazabemide hydrochloride
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Lazabemide hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for Lazabemide hydrochloride
The following data is based on the product molecular weight 236.1. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.24 mL||21.18 mL||42.35 mL|
|5 mM||0.85 mL||4.24 mL||8.47 mL|
|10 mM||0.42 mL||2.12 mL||4.24 mL|
|50 mM||0.08 mL||0.42 mL||0.85 mL|
Product Datasheets for Lazabemide hydrochloride
References for Lazabemide hydrochloride
References are publications that support the biological activity of the product.
Saura et al (1992) Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J.Neurosci. 12 1977 PMID: 1578281
Bondiolotti et al (1995) In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl. Biochem.Pharmacol. 50 97 PMID: 7605351
Guimaraes and Soares-da-Silva (1998) The activity of MAO A and B in rat renal cells and tubules. Life Sci. 62 727 PMID: 9489509
If you know of a relevant reference for Lazabemide hydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Lazabemide hydrochloride, Lazabemide hydrochloride supplier, Selective, MAO-B, inhibitors, inhibits, Monoamine, Oxygenases, Oxidases, Ro196327, Ro, 19-6327, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, 2460, Tocris Bioscience
Citations for Lazabemide hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Lazabemide hydrochloride. Do you know of a great paper that uses Lazabemide hydrochloride from Tocris? Please let us know.
Reviews for Lazabemide hydrochloride
There are currently no reviews for this product. Be the first to review Lazabemide hydrochloride and earn rewards!
Have you used Lazabemide hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.